[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363609-105":59,"doc-detail-363609-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","sex-based-responses-to-immunotherapy-in-esophageal-cancer-insights-from-a-metaanalysis","Sex-based responses to immunotherapy in esophageal cancer - insights from a metaanalysis","","Sex-based disparities in immune-related adverse events and immune response remain insufficiently characterized in esophageal cancer. This systematic review and meta-analysis evaluated whether patient sex influences the efficacy of immunotherapy. Randomized clinical trials were searched across major databases, and effect sizes were derived using hazard ratios with 95% confidence intervals. Fifteen trials were pooled to compare male versus female outcomes for overall survival and progression-free survival, alongside subgroup assessments.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/sex-based-responses-to-immunotherapy-in-esophageal-cancer-insights-from-a-metaanalysis/363609/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/sex-based-responses-to-immunotherapy-in-esophageal-cancer-insights-from-a-metaanalysis/363609.png","ImageObject",300,407,{"name":92,"@type":93},"4398046744996","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main objective of the study?","Question",{"text":112,"@type":113},"To explore the efficacy of immunotherapy in esophageal cancer based on patient sex and assess whether sex affects immune-related outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were male and female outcomes compared?",{"text":117,"@type":113},"Clinical trials were identified from multiple databases, hazard ratios with 95% confidence intervals were calculated per study, and results were pooled using meta-analytic methods in R.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results show about overall survival and progression-free survival?",{"text":121,"@type":113},"Compared with control groups, immunotherapy was associated with significantly lower hazard ratios for both overall survival and progression-free survival in males and females; subgroup analyses showed no significant efficacy differences between sexes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363609,1790236828,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":66,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":133,"file_id":134,"file_url":135,"file_type":136,"file_size":137,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":138,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},4398046744996,"Lin etal. BMCGastroenterology (2026) 26:350 [https://doi.org/10.1186/s12876-026-04834-1](https://doi.org/10.1186/s12876-026-04834-1)  \nBMC Gastroenterology  \nRESEARCH Open Access  \nSex-based responses to immunotherapy in esophageal cancer: insights from a metaanalysis  \nXiaona Lin1,2, Yinhui Jiang2, Jiakang Ma3, Yuhua Meng2,4, Changxin Zhan5,6, Yu Zhou2, Hongzheng Ren7, Guangping Zhang8, Songwang Cai1*, Shegan Gao9 and Hao Zhang10*  \nAbstract  \nBackground Sex-based disparities in immune-related adverse events and immune response remain to be fully elucidated. In this study, we aim to explore the efficacy of immunotherapy in esophageal cancer (EC) in response to patient sex.  \nMethods The study followed the guidelines of Preferred Reporting Items for the Systematic review and MetaAnalyses (PRISMA) . PubMed, EMBASE, Web of Science, Scopus, and the Cochrane Library were searched to compare immunotherapy outcomes in male and female EC patients from clinical trials. The ratio of hazard ratios (HRs) and 95% CI between males and females from each individual study was calculated and then pooled to provide a weighted average. A meta-analysis was performed using R software.  \nResults Fifteen randomized clinical trials involving 7430 male (80 .47%) and 1803 female (19 . 53%) EC patients were included. PD-1 inhibitors were most predominant immunotherapeutic interventions. Compared to control groups, patients receiving immunotherapy showed significantly lower HRs for OS and PFS in both male (OS: HR = 0 . 73, 95% CI 0.69–0. 78; PFS: HR = 0 . 56, 95% CI 0.51–0. 63) and female patients (OS: HR = 0 . 76, 95% CI 0.67–0. 87; PFS: HR = 0 . 63, 95% CI 0.54–0. 74) . Subgroup analyses revealed no significant differences in immunotherapy efficacy between two sexes. Conclusion Immunotherapy is a beneficial treatment option for EC patients of both sexes, but no significant sexbased differences in immunotherapy efficacy were observed in the current study. Future studies are warranted to investigate the efficacy disparity of different immunotherapeutic drugs in male and female patients.  \nKeywords Sex, Immunotherapy, Esophageal cancer, Meta-analysis  \n*Correspondence:  \nSongwang Cai [caisongwang@jnu.edu.cn](caisongwang@jnu.edu.cn)[ ](caisongwang@jnu.edu.cn)Hao Zhang [haolabcancercenter@163.com](haolabcancercenter@163.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nIntroduction  \nEsophageal cancer (EC) ranks as the eighth most frequently diagnosed cancers and is the sixth leading cause of cancer-related deaths worldwide [1]. It is characterized by aggressive progression and poor prognosis, with high recurrence rates even after chemotherapy or/and surgery [2]. Recent advancements, particularly the introduction of immune checkpoint inhibitors (ICIs), have revolutionized the field and offer new hope for","cbCaihz2an899hVD","https://ap.wps.com/l/cbCaihz2an899hVD","pdf",4698145,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What is the main objective of the study?\",\"answer\":\"To explore the efficacy of immunotherapy in esophageal cancer based on patient sex and assess whether sex affects immune-related outcomes.\"},{\"question\":\"How were male and female outcomes compared?\",\"answer\":\"Clinical trials were identified from multiple databases, hazard ratios with 95% confidence intervals were calculated per study, and results were pooled using meta-analytic methods in R.\"},{\"question\":\"What did the results show about overall survival and progression-free survival?\",\"answer\":\"Compared with control groups, immunotherapy was associated with significantly lower hazard ratios for both overall survival and progression-free survival in males and females; subgroup analyses showed no significant efficacy differences between sexes.\"}]","Sex-based responses to immunotherapy in esophageal cancer - insights from a metaanalysis | PDF",1790152101,33,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/769fab88c34bcf511af5b0a40697a172.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/181359c4df6f3a445e4ad265e55294b5.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a48d544f63f1d67b7fdfdd290b488b9.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30510184b3e445a69e999f1113c457f7.webp",980,1306]